Cargando…
Diagnosis and Therapeutic Management of Liver Fibrosis by MicroRNA
Remarkable progress has been made in the treatment and control of hepatitis B and C viral infections. However, fundamental treatments for diseases in which liver fibrosis is a key factor, such as cirrhosis, alcoholic/nonalcoholic steatohepatitis, autoimmune hepatitis, primary biliary cholangitis, an...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8347497/ https://www.ncbi.nlm.nih.gov/pubmed/34360904 http://dx.doi.org/10.3390/ijms22158139 |
_version_ | 1783735103842680832 |
---|---|
author | Tadokoro, Tomoko Morishita, Asahiro Masaki, Tsutomu |
author_facet | Tadokoro, Tomoko Morishita, Asahiro Masaki, Tsutomu |
author_sort | Tadokoro, Tomoko |
collection | PubMed |
description | Remarkable progress has been made in the treatment and control of hepatitis B and C viral infections. However, fundamental treatments for diseases in which liver fibrosis is a key factor, such as cirrhosis, alcoholic/nonalcoholic steatohepatitis, autoimmune hepatitis, primary biliary cholangitis, and primary sclerosing cholangitis, are still under development and remain an unmet medical need. To solve this problem, it is essential to elucidate the pathogenesis of liver fibrosis in detail from a molecular and cellular perspective and to develop targeted therapeutic agents based on this information. Recently, microRNAs (miRNAs), functional RNAs of 22 nucleotides, have been shown to be involved in the pathogenesis of liver fibrosis. In addition, extracellular vesicles called “exosomes” have been attracting attention, and research is being conducted to establish noninvasive and extremely sensitive biomarkers using miRNAs in exosomes. In this review, we summarize miRNAs directly involved in liver fibrosis, miRNAs associated with diseases leading to liver fibrosis, and miRNAs related to complications of cirrhosis. We will also discuss the efficacy of each miRNA as a biomarker of liver fibrosis and pathology, and its potential application as a therapeutic agent. |
format | Online Article Text |
id | pubmed-8347497 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-83474972021-08-08 Diagnosis and Therapeutic Management of Liver Fibrosis by MicroRNA Tadokoro, Tomoko Morishita, Asahiro Masaki, Tsutomu Int J Mol Sci Review Remarkable progress has been made in the treatment and control of hepatitis B and C viral infections. However, fundamental treatments for diseases in which liver fibrosis is a key factor, such as cirrhosis, alcoholic/nonalcoholic steatohepatitis, autoimmune hepatitis, primary biliary cholangitis, and primary sclerosing cholangitis, are still under development and remain an unmet medical need. To solve this problem, it is essential to elucidate the pathogenesis of liver fibrosis in detail from a molecular and cellular perspective and to develop targeted therapeutic agents based on this information. Recently, microRNAs (miRNAs), functional RNAs of 22 nucleotides, have been shown to be involved in the pathogenesis of liver fibrosis. In addition, extracellular vesicles called “exosomes” have been attracting attention, and research is being conducted to establish noninvasive and extremely sensitive biomarkers using miRNAs in exosomes. In this review, we summarize miRNAs directly involved in liver fibrosis, miRNAs associated with diseases leading to liver fibrosis, and miRNAs related to complications of cirrhosis. We will also discuss the efficacy of each miRNA as a biomarker of liver fibrosis and pathology, and its potential application as a therapeutic agent. MDPI 2021-07-29 /pmc/articles/PMC8347497/ /pubmed/34360904 http://dx.doi.org/10.3390/ijms22158139 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Tadokoro, Tomoko Morishita, Asahiro Masaki, Tsutomu Diagnosis and Therapeutic Management of Liver Fibrosis by MicroRNA |
title | Diagnosis and Therapeutic Management of Liver Fibrosis by MicroRNA |
title_full | Diagnosis and Therapeutic Management of Liver Fibrosis by MicroRNA |
title_fullStr | Diagnosis and Therapeutic Management of Liver Fibrosis by MicroRNA |
title_full_unstemmed | Diagnosis and Therapeutic Management of Liver Fibrosis by MicroRNA |
title_short | Diagnosis and Therapeutic Management of Liver Fibrosis by MicroRNA |
title_sort | diagnosis and therapeutic management of liver fibrosis by microrna |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8347497/ https://www.ncbi.nlm.nih.gov/pubmed/34360904 http://dx.doi.org/10.3390/ijms22158139 |
work_keys_str_mv | AT tadokorotomoko diagnosisandtherapeuticmanagementofliverfibrosisbymicrorna AT morishitaasahiro diagnosisandtherapeuticmanagementofliverfibrosisbymicrorna AT masakitsutomu diagnosisandtherapeuticmanagementofliverfibrosisbymicrorna |